Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer

Pfizer released a financial outlook for next year that that doesn’t match with Wall Street expectations as sales of COVID-19 products slide. Shares tumbled more than 7% before the opening bell Wednesday. In October, the drugmaker reported quarterly losses of more than $2 billion as falling sales of COVID-19 products clipped revenue.